MedTrace Logo

Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients

NCT00150046 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2020-02-11

No results posted yet for this study

Summary

This study will test the safety and efficacy of everolimus on heart transplant recipients.

This study is not recruiting in the United States.

Conditions

  • Heart Transplantation

Interventions

DRUG

Everolimus

Sponsors & Collaborators

Principal Investigators

  • Basel Novartis Pharma AG · Basel Novartis Pharma AG

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2007-05-31

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00150046 on ClinicalTrials.gov